ROCKWELL MEDICAL, INC.
For the period ended Apr 30, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Apr 30, 2026 · Filed Apr 30, 2026
Use the contents to explore the available documents and sections.
Contents
Background
Our Board is divided into three classes, designated Class I, Class II and Class III. Each year, on a rotating basis and until their successor has been elected and qualified, the terms of office of the directors in one of the three classes expire. Successors to the class of directors whose terms have expired will be elected for a three-year term. The terms of each of the Class II Directors will expire at the Annual Meeting, the terms of each of the Class III Directors will expire at the 2027 annual meeting of stockholders and the terms of each of the Class I Directors will expire at the 2028 annual meeting of stockholders, in each case upon the election and qualification of the applicable successors.
Set forth below are the names and certain information for each continuing member of the Board, including the nominees for election as Class II directors, as of March 1, 2026. Former director Andrea Heslin Smiley resigned from the Board effective November 17, 2025. Mr. Ravich is not standing for reelection at the Annual Meeting. The size of the Board will be reduced to six members once Mr. Ravich’s term concludes at the Annual Meeting. The information presented includes each director’s and nominee’s principal occupation and business experience for the past five years, and the names of other public companies of which he or she has served as a director during the past five years. The information presented below regarding the specific experience, qualifications, attributes and skills of each director and nominee led our Nominating and Governance Committee and our Board to conclude that he or she should serve as a director. In addition, we believe that all of our directors and nominees possess the attributes or characteristics described in “Corporate Governance—Nominating and Governance Committee” that the Nominating and Governance Committee expects of each director. There are no family relationships among any of our directors, nominees for director, or executive officers.
| Name | Age | Position(s) |
|---|---|---|
| Class I Directors: | ||
| Allen Nissenson, MD(1)(3) | 79 | Director |
| John G. Cooper(1)(2) | 67 | Director |
| Class II Directors: | ||
| Joseph Dawson | 61 | Director |
| Joan Lau, Ph.D.(1)(2) | 55 | Director |
| Mark H. Ravich(2)(3) | 73 | Director |
| Class III Directors: | ||
| Mark Strobeck, Ph.D. | 55 | President and Chief Executive Officer, Director |
| Robert S. Radie(3) | 62 | Chairman |
(1)Member of the Compensation Committee.
(2)Member of the Audit Committee.
(3)Member of the Nominating and Governance Committee.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.